These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 9084225)

  • 1. [Quantitative evaluation of pharmacological effects and adverse effects based on receptor occupancy theory].
    Sawada Y; Yamada Y; Iga T
    Yakugaku Zasshi; 1997 Feb; 117(2):65-90. PubMed ID: 9084225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Research tools for extrapolating the disposition and pharmacokinetics of nanomaterials from preclinical animals to humans.
    Valic MS; Zheng G
    Theranostics; 2019; 9(11):3365-3387. PubMed ID: 31244958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variations of pharmacokinetics of drugs in patients with cirrhosis.
    Pena MA; Horga JF; Zapater P
    Expert Rev Clin Pharmacol; 2016; 9(3):441-58. PubMed ID: 26696448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A model-based assay design to reproduce in vivo patterns of acute drug-induced toxicity.
    Kuepfer L; Clayton O; Thiel C; Cordes H; Nudischer R; Blank LM; Baier V; Heymans S; Caiment F; Roth A; Fluri DA; Kelm JM; Castell J; Selevsek N; Schlapbach R; Keun H; Hynes J; Sarkans U; Gmuender H; Herwig R; Niederer S; Schuchhardt J; Segall M; Kleinjans J
    Arch Toxicol; 2018 Jan; 92(1):553-555. PubMed ID: 28852801
    [No Abstract]   [Full Text] [Related]  

  • 5. On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models.
    Lowe PJ; Tannenbaum S; Wu K; Lloyd P; Sims J
    Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):195-209. PubMed ID: 20050847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microdosing Studies in Children: A US Regulatory Perspective.
    Roth-Cline M; Nelson RM
    Clin Pharmacol Ther; 2015 Sep; 98(3):232-3. PubMed ID: 26095312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Physiolgically-based pharmacokinetics:Theory and examples.].
    Ishimoto T; Kato Y
    Clin Calcium; 2016; 26(11):1529-1537. PubMed ID: 27777386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Commentary on 'Designs for dose-escalation trials with quantitative responses'.
    Senn S
    Stat Med; 2009 Dec; 28(30):3754-8; discussion 3759-60. PubMed ID: 19967754
    [No Abstract]   [Full Text] [Related]  

  • 9. Microdosing for reduction of the time and resources for drug development.
    Sudo K
    Drug Metab Pharmacokinet; 2007 Oct; 22(5):327. PubMed ID: 17965515
    [No Abstract]   [Full Text] [Related]  

  • 10. The utility of microdosing over the past 5 years.
    Lappin G; Garner RC
    Expert Opin Drug Metab Toxicol; 2008 Dec; 4(12):1499-506. PubMed ID: 19040326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug dosage in the elderly. Is it rational?
    Turnheim K
    Drugs Aging; 1998 Nov; 13(5):357-79. PubMed ID: 9829164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacokinetics: current requirements and future perspectives from a regulatory point of view.
    Shah RR
    Xenobiotica; 1993 Nov; 23(11):1159-93. PubMed ID: 8310705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adaptive control of drug dosage regimens: basic foundations, relevant issues, and clinical examples.
    Jelliffe RW; Maire P; Sattler F; Gomis P; Tahani B
    Int J Biomed Comput; 1994 Jun; 36(1-2):1-23. PubMed ID: 7927847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The biopharmaceutics risk assessment roadmap for optimizing clinical drug product performance.
    Selen A; Dickinson PA; Müllertz A; Crison JR; Mistry HB; Cruañes MT; Martinez MN; Lennernäs H; Wigal TL; Swinney DC; Polli JE; Serajuddin ATM; Cook JA; Dressman JB
    J Pharm Sci; 2014 Nov; 103(11):3377-3397. PubMed ID: 25256402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In silico methods to predict drug toxicity.
    Roncaglioni A; Toropov AA; Toropova AP; Benfenati E
    Curr Opin Pharmacol; 2013 Oct; 13(5):802-6. PubMed ID: 23797035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling and predicting drug pharmacokinetics in patients with renal impairment.
    Rowland Yeo K; Aarabi M; Jamei M; Rostami-Hodjegan A
    Expert Rev Clin Pharmacol; 2011 Mar; 4(2):261-74. PubMed ID: 22115405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. De-risking drug discovery with ADDME -- avoiding drug development mistakes early.
    Tsaioun K; Jacewicz M
    Altern Lab Anim; 2009 Sep; 37 Suppl 1():47-55. PubMed ID: 19807206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Utility of a microdose study for drug discovery and development].
    Yamaura Y
    Nihon Yakurigaku Zasshi; 2013 Mar; 141(3):126-30. PubMed ID: 23470476
    [No Abstract]   [Full Text] [Related]  

  • 19. Dynamical dosage regimen calculations in linear pharmacokinetics.
    Iliadis A; Bruno R; Cano JP
    Comput Biomed Res; 1988 Jun; 21(3):203-20. PubMed ID: 3383552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosage regimen calculations with optimal control theory.
    Iliadis A; Barbolosi D
    Int J Biomed Comput; 1994 Jun; 36(1-2):87-93. PubMed ID: 7927863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.